Ultrasound-enhanced Thrombolysis

J Endovasc Ther. 2007 Apr;14(2):251-6. doi: 10.1177/152660280701400218.

Abstract

Purpose: To report a single-center clinical experience with ultrasound-enhanced thrombolysis in the treatment of both arterial and venous thromboses.

Methods: From January 2005 to June 2006, 33 patients (23 men; age range 39-90 years) with 36 occlusions were treated using ultrasound-enhanced thrombolytic therapy for acute and chronic arterial and venous occlusions. After diagnostic angiography, the occlusions were crossed with an appropriately sized Lysus infusion catheter for infusion of urokinase (80,000-120,000 IU/h).

Results: Technical success and complete lysis was achieved in 96% of the arterial and 83% of the venous occlusions. Two patients with chronic occlusions (one superficial femoral artery and one iliac vein) were refractory to lytic therapy. Average time for complete lysis was 16.4 hours (range 3-25) for arterial occlusions and 21.2 hours (range 6-43) in patients with deep vein thrombosis.

Conclusion: Successful clot lysis can be achieved with a high rate of success in a shorter time than conventional thrombolysis using ultrasound-enhanced thrombolysis in both acute and chronic arterial and venous thromboses.

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Aged, 80 and over
  • Arterial Occlusive Diseases / diagnostic imaging
  • Arterial Occlusive Diseases / drug therapy
  • Arterial Occlusive Diseases / physiopathology
  • Arterial Occlusive Diseases / therapy*
  • Chronic Disease
  • Combined Modality Therapy
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Radiography, Interventional
  • Recurrence
  • Thrombolytic Therapy* / instrumentation
  • Thrombosis / diagnostic imaging
  • Thrombosis / drug therapy
  • Thrombosis / physiopathology
  • Thrombosis / therapy*
  • Time Factors
  • Treatment Outcome
  • Ultrasonic Therapy* / instrumentation
  • Urokinase-Type Plasminogen Activator / therapeutic use*
  • Vascular Patency
  • Venous Thrombosis / drug therapy
  • Venous Thrombosis / therapy

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator